OpenAI Eyes Autonomous Research Breakthrough
San Francisco tech giant OpenAI is setting its sights on a truly ambitious goal: creating a fully automated AI researcher. This isn’t just about building a smarter chatbot; the company envisions an agent-based system capable of independently tackling complex scientific problems. Company chief scientist Jakub Pachocki revealed this ambitious “north star” initiative, with plans to debut an “autonomous AI research intern” by September. This intern will serve as a stepping stone towards a more advanced, multi-agent system slated for a 2028 release. This push signals a significant shift in AI development, moving beyond task-specific tools towards genuine scientific discovery engines.
Psychedelic Research Faces Hurdles
Meanwhile, the burgeoning field of psychedelic research, once hailed for its potential to treat conditions like depression and PTSD, is encountering significant obstacles. Recent studies underscore the inherent difficulties in conducting rigorous clinical trials for these mind-altering substances. Despite a decade of escalating scientific interest in compounds like psilocybin, the path to proving their efficacy in a controlled, scientific manner is proving to be far more complex than initially anticipated, raising questions about the current hype surrounding these drugs.
📰 Source: MIT Tech Review
